[1]. Aronov AM, et al. Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control. J. Med. Chem., 52 (20): 6362–6368 (2009).
[2]. Carlino MS, et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology 8(3): 544–554 (2014).
[3]. Krepler C, et al. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 22(7): 1592-1602 (2015).